From 5AM's nest, neuroscience startup Nido Biosciences launches with $109M and PhI underway

Kyle LaHucik

Senior Reporter

After almost five years in stealth, precision neuroscience startup Nido Biosciences emerged Monday with $109 million and a Phase I study already in the works …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

From 5AM's nest, neuroscience startup Nido Biosciences launches with $109M and PhI underway

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

From 5AM's nest, neu­ro­science start­up Nido Bio­sciences launch­es with $109M and PhI un­der­way

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Genen­tech vet launch­es ADC start­up with $20M

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

From 5AM's nest, neuroscience startup Nido Biosciences launches with $109M and PhI underway

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence